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Abstract
Head and neck squamous cell carcinoma (HNSCC) is responsible for approximately 20,000 deaths per year in the United
States. Most of the deaths are due to the metastases. To develop more effective strategies for the prevention of metastasis
of HNSCC cells, we have determined the effect of grape seed proanthocyanidins (GSPs) on the invasive potential of HNSCC
cell and the mechanisms underlying these effects using OSC19 cells as an in vitro model. Using cell invasion assays, we
established that treatment of the OSC19 cells with GSPs resulted in a dose-dependent inhibition of cell invasion. EGFR is
over-expressed in 90% of HNSCCs and the EGFR inhibitors, erlotinib and gefitinib, are being explored as therapies for this
disease. We found that GSPs treatment reduced the levels of expression of EGFR in the OSC19 cells as well as reducing the
activation of NF-kB/p65, a downstream target of EGFR, and the expression of NF-kB-responsive proteins. GSPs treatment
also reduced the activity of ERK1/2, an upstream regulator of NF-kB and treatment of the cells with caffeic acid phenethyl
ester, an inhibitor of NF-kB, inhibited cell invasion. Overexpression of EGFR and high NF-kB activity play a key role in the
epithelial-to-mesenchymal transition, which is of critical importance in the processes underlying metastasis, and we found
treatment with GSPs enhanced the levels of epithelial (E-cadherin, cytokeratins and desmoglein-2) and reduced the levels of
mesenchymal (vimentin, fibronectin, N-cadherin and Slug) biomarkers in the OSC19 cells. These results indicate that GSPs
have the ability to inhibit HNSCC cell invasion, and do so by targeting the expression of EGFR and activation of NF-kB as well
as inhibiting the epithelial-to-mesenchymal transition.
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Introduction
Squamous cell carcinoma of the head and neck (HNSCC) is the
sixth most commonly occurring malignancy world-wide. It is
responsible for approximately 20,000 deaths and affects more than
40,000 people in the United States annually [1,2]. HNSCCs
exhibit aggressive behavior with a high incidence of secondary
primaries in the head and neck (5–7% per year) together with a
high incidence of distant metastases. This potent metastatic
capacity is associated closely with the high mortality rate.
Advances in surgical and medical therapies for HNSCC have
resulted in only a modest improvement in the mortality rate,
which has remained at approximately 50% for the last three
decades [3–6]. Currently available therapies including conven-
tional chemotherapy and surgical resection are often associated
with severe morbidity due to the involvement of vital structures of
the head and neck, side effects and therapeutic resistance.
Therefore, elucidation of the molecular pathways essential for
metastasis and identification of approaches that minimize the
invasive and metastatic behaviors of cancer cells is of high priority
in the treatment of patients with HNSCC and in chemopreven-
tion.
Naturally occurring bioactive dietary phytochemicals that are
non-toxic and devoid of major side effects are candidates for the
prevention of recurrence or metastasis of cancer cells. Such agents
can be utilized as complementary and alternative medicine and/or
as adjuvant therapy for conventional cytotoxic therapies. The
seeds of grapes (Vitis vinifera L.) are a rich source of proanthocya-
nidins and these grape seed proanthocyanidins (GSPs) are
promising bioactive phytochemicals that have shown anti-
carcinogenic effects in some tumor models with no apparent signs
of toxicity in these animal models [7–9]. In spite of the anti-
carcinogenic effects of GSPs [7], their chemotherapeutic effects on
the invasive potential of HNSCC cells have not been assessed.
Epidermal growth factor receptor (EGFR) appears to play a
critical role in HNSCC. It is overexpressed in almost all HNSCC
tumors (.90%) and its overexpression is associated with poor
prognosis [10–12]. It has been reported that small molecule
inhibitors of EGFR, such as erlotinib and gefitinib, can prevent the
growth and progression of HNSCCs [13]. A downstream target of
EGFR, the transcription factor nuclear factor-kappaB (NF-kB),
also has been shown to be essential for metastasis in models of
cancer progression [14]. The overexpression of EGFR, enhanced
EGFR-associated signaling, and enhanced NF-kB activity have all
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During EMT, cancer cells lose expression of proteins that promote
cell-cell contact, such as E-cadherin, and acquire mesenchymal
markers, such as vimentin, fibronectin and N-cadherin, that
promote tumor progression, cell invasion and metastasis [15,16].
In the present communication, we explored the chemotherapeutic
effects of GSPs on the invasive potential of human HNSCC cells
and ascertained whether EGFR and its associated pathways are
involved in this process. Comparison of the invasive potential of
several different HNSCC cell lines derived from different sub-sites
indicated that the OSC19 cell line exhibited the greatest invasive
potential and this cell line was used in all subsequent studies. We
report that GSPs inhibit the invasive potential of the OSC19
HNSCC cells through inhibition or reversal of EMT and that this
GSPs-induced inhibition is accomplished through a process that
involves a reduction in the levels of EGFR expression, inactivation
of NF-kB and inactivation of Erk1/2.
Materials and Methods
Source of the grape seed proanthocyanidins
The GSPs preparation was received from the Kikkoman
Company, Noda, Japan (no financial conflict of interest) and used
throughout the study. Quality control of the GSPs preparation is
maintained by the company on lot-to-lot basis. The GSPs
preparation contains approximately 89% proanthocyanidins, with
dimers (6.6%), trimers (5.0%), tetramers (2.9%) and oligomers
(74.8%), as described earlier [7–9]. The product is stable for at
least two years when refrigerated at 4uC.
Chemicals, reagents and antibodies
Boyden Chambers and polycarbonate membranes (8 mm pore
size) for cell migration/invasion assays were obtained from
Neuroprobe, Inc. (Gaithersburg, MD). The antibodies specific
for N-cadherin, keratin 8, keratin 18, fibronectin, EGFR, ERK1/
2, cyclooxygenase-2 (COX-2), matrix metalloproteinase (MMP)-2,
MMP-9, inducible nitric oxide synthase (iNOS) and b-actin were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA), while
antibodies for vimentin, E-cadherin, Slug, NF-kB, IkB kinase a
(IKKa), IkBa and vascular endothelial growth factor (VEGF) were
purchased from Cell Signaling Technology (Beverly, MA), while
desmoglein 2 was obtained from Abcam (Cambridge, MA). The
appropriate secondary antibodies conjugated with horseradish
peroxidase were procured from Invitrogen (Carlsband, CA).
UO126, an inhibitor of the mitogen-activated/extracellular
protein-regulated kinase (MEK), was purchased from Sigma
Chemical Co. (St. Louis, MO). Erlotinib was procured from
Santa Cruz Biotechnology and gefitinib from Toronto Research
Chemicals, Inc. (North York, ON, Canada).
Cell lines and cell culture conditions
HNSCC cell lines derived from the oral cavity (UM-SCC1),
larynx (UM-SCC5), pharynx (FaDu) and tongue (OSC19) were
obtained from Dr. Rosenthal (University of Alabama at Birming-
ham, Birmingham, AL). The OSC19 cell line was developed from
tumor cells that had metastasized to the lymph node from an
HNSCC of the tongue. The cells were cultured as monolayers in
DMEM supplemented with 10% heat-inactivated fetal bovine
serum and 100 mg/mL penicillin-streptomycin (Invitrogen), and
kept in a humidified atmosphere of 5% CO2 at 37uC. Cells were
seeded at a density of 1610
6 cells per culture dish and allowed to
attach for 24 h, at which time they were sub-confluent, before
treatment with GSPs or other agents. The GSPs, erlotinib or
gefitinib were dissolved in a small amount of dimethylsulfoxide
(DMSO), which was added to the complete cell culture medium.
The maximum concentration of DMSO in media was 0.1% (v/v).
Cells treated with DMSO only served as a vehicle control.
Cell proliferation assay
The effect of GSPs on the viability or cell proliferation of
normal human bronchial epithelial cells or human HNSCC cells
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide assay (Sigma) or MTT assay, as previously
described [17]. A total of 1610
4 cells per well in 200 mL complete
medium were seeded in a 96-well plate and treated with varying
concentrations of GSPs for 48 h. The cells were treated with
50 mL of 5 mg/mL MTT and the resulting formazan crystals were
dissolved in dimethylsulfoxide (200 mL). Absorbance was recorded
at 540 nm with a reference at 650 nm serving as the blank. The
effect of GSPs on cell viability was assessed as percent cell viability
compared to vehicle-treated control cells, which were arbitrarily
assigned 100% viability. All treatment concentrations were
repeated in six wells.
Cell death assay
The trypan blue dye exclusion assay was used to determine the
cytotoxic effect of GSPs on the cells. Briefly, 5610
4 cells were
cultured into each well of a six-well culture plates. After overnight
incubation, the cells were treated with varying concentrations of
GSPs (0, 10, 20, 40 mg/mL) for 48 h. Thereafter cells were
harvested, treated with 0.25% trypan blue dye and the cells that
had taken up the dye were counted under a microscope using a
hemocytometer, as detailed previously [17]. The cytotoxic effects
of GSPs are expressed as the mean6SD percentage of dead cells
in each treatment group from three repeated experiments.
Figure 1. Analysis of invasive potential of HNSCC cell lines. (A)
The invasion potential of several human HNSCC cell lines including
SCC1 (derived from the oral cavity), SCC5 (derived from the larynx),
FaDu (derived from the pharynx) and OSC19 (derived from a lymph-
node metastases from the tongue) were assessed using a Boyden
chamber cell invasion assay. Equal numbers of cells were loaded and
after 48 h incubation, invasive cells were detected on the membrane by
staining with crystal violet. (B) The invasive cells were counted and the
results expressed as the mean number of invasive cells6SD/micro-
scopic field, magnification: 610. Significantly higher versus other cells,
*P,0.001.
doi:10.1371/journal.pone.0031093.g001
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The invasion capacity of HNSCC cells was determined in vitro
using Boyden Chambers (Gaithersburg, MD). In this assay, the
two chambers were separated with Matrigel-coated Millipore
membranes (6.5 mm diameter filters, 8 mM pore size), as
detailed previously [18,19]. Briefly, cells (1.5610
4 cells/
100 mL serum-reduced [0.5% FBS] medium) were placed in
the upper chamber of the Boyden chambers and the test agents
were added alone, or in combination, to the upper chamber
(200 mL). The lower chamber contained the medium alone
(150 mL). The chambers were assembled and kept in a cell
culture incubator for the specified periods of time. After
incubation, cells from the upper surface of the Millipore
membranes were removed with gentle swabbing and the cells
on the lower surface of membranes were fixed and stained with
crystal violet. The membranes were examined microscopically
and cellular invasion was determined by counting the migrat-
ing/invasive cells on each membrane in at least 4–5 randomly
selected fields using an Olympus BX41 microscope. Represen-
tative photomicrographs were obtained using a Qcolor5 digital
camera system fitted to an Olympus BX41 microscope. Each
experiment was repeated three times and the resultant cell
invasion data are presented in terms of the mean number of
invasive or migrating cells6SD/microscopic field (magnifica-
tion, 610) from three independent experiments.
Assay for NF-kB/p65 activity
The NF-kB Trans
AM Activity Assay Kit (Active Motif,
Carlsbad, CA) was used for quantitative analysis of NF-kB/p65
activity following the manufacturer’s protocol. For this purpose,
the nuclear extracts of cells from various treatment groups were
prepared using the Nuclear Extraction Kit (Active Motif,
Carlsbad, CA) following the manufacturer’s instructions and as
described previously [20]. Briefly, this assay kit is an ELISA-based
kit to detect and quantify NF-kB activation. By using an antibody
that is directed against the NF-kB/p65 subunit, the activated NF-
kB/p65 subunit bound to the oligonucleotide is detected. Addition
of a secondary antibody conjugated to horseradish peroxidase
provides sensitive colorimetric readout that is easily quantified by
spectrophotometer. The manufacturer suggests that this NF-kB/
p65 Trans
AM activity assay kit is more sensitive than EMSA.
Absorbance was recorded at 450 nm using absorbance at 650 nm
as the reference. The results are expressed as the percentage of the
optical density of the non-GSPs-treated control group.
Figure 2. Effect of GSPs on HNSCC cell invasion and EGFR expression. (A) OSC19 cells were treated with the indicated concentrations of
GSPs for 48 h and the effects on their invasiveness assessed as described in Figure 1. Crystal violet staining of the membranes showed that, as
compared to non-GSPs-treated control cells, the GSPs inhibited invasion of cells in a concentration-dependent manner. (B) The migratory cells were
counted and the results expressed as the mean number of invasive cells6SD/microscopic field, magnification: 610. The values are reported from
three separate experiments. Significant inhibition versus non-GSPs-treated control,
*P,0.001,
"P,0.01. (C) The non-toxic effect of GSPs on normal
human bronchial epithelial cells was determined in terms of cell viability and cell death. The data on cell viability are expressed in terms of percent of
control cells (non-GSPs-treated) as the mean6SD of 6 replicates. Similarly, the cytotoxic effect of GSPs on normal bronchial epithelial cells was
determined using trypan blue dye exclusion assay as described in Materials and Methods and is expressed in terms of percent of dead cells as
mean6SD from three experiments. (D) Dose-dependent effect of GSPs on EGFR expression in OSC19 cells. The levels of EGFR in whole cell lysates of
OSC19 cells treated with different concentrations of GSPs for 48 h were determined using western blot analysis. Representative blots are shown from
three independent experiments.
doi:10.1371/journal.pone.0031093.g002
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A f t e ri n c u b a t i o no fc e l l sf o rt h eindicated time periods with or
without the treatment of GSPs or other agents, the cells were
harvested, washed with cold PBS and lysed with ice-cold lysis
buffer supplemented with protease inhibitors, as detailed
previously [18,19]. Cytoplasmic and nuclear protein fractions
were prepared separately for the analysis of respective proteins.
The purity of cytoplasmic and nuclear fractions was tested. The
absence of b-actin in nuclear fraction confirms its purity while
absence of Lamin B or Histone H3 proteins in cytoplasmic
fraction suggests that this fraction is free from nuclear fraction.
The purity was confirmed using western blot analysis. Proteins
(30–50 mg) were resolved on 10% Tris-Glycine gels and
transferred onto a nitrocellulose membrane. After blocking the
non-specific binding sites, the membrane was incubated with the
primary antibody at 4uC overnight. The membrane was then
incubated with the appropriate peroxidase-conjugated second-
ary antibody and the specific-protein bands were visualized
using the enhanced chemiluminescence reagents. The equal
loading of protein samples on the gel was verified after stripping
and re-probing of the membrane with anti-b-actin antibody.
Representative blots are shown from three independent
experiments.
Statistical analysis
For statistical analysis of cell invasion assays, the control,
gefitinib, erlotinib or GSPs treatment groups or combined-
treatment groups separately were compared using one-way
analysis of variance (ANOVA) followed by the post hoc Dunn’s
test using GraphPad Prism version 4.00 for Windows software
(GraphPad Software, San Diego, California. www.graphpad.com.)
All quantitative data for cell migration are shown as the mean
number of migrating cells6SD/microscopic field from at least
three independent experiments. In each case P,0.05 was
considered statistically significant.
Results
Analysis of the invasive potential of human HNSCC cells
First, we assessed the invasion capacity of various HNSCC
cell lines that originated from different sub-sites of the head and
neck, including the oral cavity (SCC1), larynx (SCC5), pharynx
(FaDu) and tongue (OSC19) using a modified Boyden chamber
assay. Incubation of the HNSCC cells for 48 h resulted in a
greater number of invasive cells than incubation for 24 h.
Representative photographs of crystal violet-stained membranes
are shown in Figure 1A. As shown in Figure 1B, calculation of
the cell invasion data in terms of the mean number of invasive
cells6SD/microscopic field (magnification, 610), the invasion
capacity of OSC19 cells was found to be greater (380616 cells/
microscopic field) than SCC1 (7567), SCC5 (3864) and FaDu
(5865) cells. The invasion capacity of OSC19 cells was signi-
ficantly higher (P,0.001) than that of SCC1, SCC5 and FaDu
cells. Under identical conditions, the migration of normal
human bronchial epithelial cells was hardly detectable (data not
shown). As the invasive potential of OSC19 cells was signi-
ficantly greater than other HNSCC cell lines tested under the
conditions of this assay, the OSC19 cell line was selected for
further studies.
GSPs inhibit the invasive potential of OSC19 cells
To determine whether bioactive phytochemicals have the ability
to inhibit the invasive potential of HNSCC cells, we used GSPs as
a test agent in the in vitro cell invasion assay described above. As
shown in Figure 2, as compared to non-GSPs-treated control cells,
the treatment of cells with GSPs at the concentrations of 10, 20
and 40 mg/mL for 48 h reduced the invasive potential of OSC19
cells in a concentration-dependent manner. The density of the
migrating cells on the membrane after staining with crystal violet is
shown in Figure 2A, and a summary of the mean numbers of
invasive cells6SD/microscopic field is provided in Figure 2B. The
cell invasion potential of the OSC19 cells was inhibited by 41–
Figure 3. Effect of the EGFR inhibitors, gefitinib and erlotinib,
on HNSCC cell invasion. (A) OSC19 cells were treated with the
indicated concentrations of erlotinib, a small molecule inhibitor of
EGFR, for 48 h and the effects on invasion assessed as described in
Figure 1. Crystal violet staining of the membrane shows that erlotinib
inhibited invasion of OSC19 cells in a concentration-dependent manner.
(B) The invasive cells were counted and the results expressed as the
mean number of invasive cells6SD/microscopic field, magnification:
610. (C) Similarly, treatment of OSC19 cells with the indicated
concentrations of gefitinib, a small molecule inhibitor of tyrosine kinase
activity and, thus, of EGFR, inhibited cell invasion in a dose-dependent
manner as indicated by crystal violet staining of the membrane. (D) The
invasive cells from the experiment described in Figure 3C were counted
and the results expressed as the mean number of invasive cells6SD/
microscopic field, magnification: 610. Significant reduction of cell
invasion versus untreated control cells,
"P,0.05,
*P,0.001.
doi:10.1371/journal.pone.0031093.g003
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treatment with GSPs. To verify that the inhibition of invasion of
OSC19 cells by the GSPs was due to a direct effect on migration
ability, and was not due to a reduction in cell viability, a trypan
blue assay was performed using cells that were treated identically
to those used in the cell invasion assays. Treatment of OSC19 cells
with various concentrations of GSPs (0, 10, 20 and 40 mg/mL) for
48 h had no significant effect on cell viability or induction of cell
death (data not shown). Similarly, we also checked the toxic effects
of GSPs on normal bronchial epithelial cells in vitro. These cells
were treated with various concentrations of GSPs for 24 and 48 h
under identical conditions. As shown in Figure 2C, treatment of
cells with GSPs did not reduce significantly the proliferation ability
or viability of cells as well as could not induce significant cell death
under the experimental conditions used in this study. These data
suggest that GSPs are not toxic to normal bronchial epithelial cells.
Figure 4. Effect of GSPs and erlotinib on NF-kB activation in OSC19 cells. (A) Treatment of OSC19 cells with GSPs decreases the basal levels
of NF-kB/p65 and IKKa while inhibiting the degradation of IkBa. After treatment of cells for 48 h with various concentrations of GSPs the cells were
harvested, cytosolic and nuclear fractions were prepared and these were subjected to western blot analysis. Representative blots are shown from
three independent experiments with identical observations. (B) The activity of NF-kB/p65 in the nuclear fraction of cells after treatment with and
without GSPs was measured using an NF-kB/p65-specific activity assay kit, n=3. Activity of NF-kB/p65 is expressed in terms of percent of the control
(non-GSPs-treated) group. Significant decrease versus control:
"P,0.05,
*P,0.001. (C) Similarly, treatment of OSC19 cells with erlotinib reduced the
levels of NF-kB and IKKa. Representative blots are shown from two independent experiments. (D) The activity of NF-kB/p65 in the nuclear fraction of
cells after treatment with and without erlotinib for 48 h was measured using the NF-kB/p65-specific activity assay kit, n=2. Activity of NF-kB/p65 is
expressed in terms of percent of control (non-erlotinib-treated) group. Significant decrease versus control:
*P,0.001. (E) Treatment of OSC19 cells
with caffeic acid phenethyl ester (CAPE), an inhibitor of NF-kB, for 48 h inhibited cell invasion in a concentration-dependent manner. Data on cell
invasion are summarized as the mean number of invasive cells6SD/microscopic field from three independent experiments, magnification: 610.
Significant inhibition versus non-CAPE-treated cells,
*P,0.001,
"P,0.05. (F) GSPs reduce the levels of NF-kB-targeted proteins, such as MMP-2, MMP-9,
COX-2, iNOS and VEGF, in OSC19 cells. After treatment of cells with and without GSPs for 48 h, cells were harvested, and cell lysates were subjected to
the analysis of the levels of proteins using western blot analysis. Representative blots are shown from three independent experiments.
doi:10.1371/journal.pone.0031093.g004
Proanthocyanidins Inhibit Invasion of HNSCC Cells
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e31093Treatment of cells with GSPs reduces the level of EGFR
expression
As it has been shown that EGFR is overexpressed in over 90%
of HNSCC tumors [10–12], we determined whether inhibition of
cell invasion of OSC19 cells by GSPs is associated with a reduction
in the expression of EGFR. For this purpose, whole cell lysates
from different treatment groups were analyzed by western blotting.
As shown in Figure 2D, treatment of OSC19 cells with GSPs for
48 h resulted in a reduction in the levels of EGFR expression in a
concentration-dependent manner as compared to the expression
of EGFR in non-GSPs-treated controls. These results suggest that
the GSPs-induced reduction in EGFR expression may be
associated with an inhibitory effect of the GSPs on the invasive
potential of these cells.
The EGFR inhibitors, erlotinib and gefitinib, inhibit the
invasive potential of OSC19 cells
We next examined the effects of the erlotinib, a selective
inhibitor of EGFR, and gefitinb, a kinase inhibitor that inhibits
EGFR, on the cell invasion potential of the OSC19 cells. For this
purpose, cells were incubated with various concentrations of
erlotinib (0, 0.1, 1.0 and 10.0 mM) for 48 h in Boyden chambers.
As shown in Figure 3A, treatment of the cells with erlotinib
resulted in a dose-dependent reduction in the cell invasion
capacity of OSC19 cells as reflected by the presence of invasive
cells on the membrane compared with non-erlotinib-treated
controls. The resultant data on cell invasion was determined in
terms of the number of invasive cells/microscopic field6SD at
different concentrations of erlotinib and are summarized in
Figure 3B. Similar results were obtained when OSC19 cells were
treated with gefitinib. Resultant data on cell invasion which are
shown in Figure 3C and are summarized in Figure 3D,
demonstrated that the treatment of OSC19 cells with gefitinib
for 48 h under identical conditions resulted in a dose-dependent
inhibition of cell invasion. These results support the concept that
the GSPs may act to inhibit the invasion of OSC19 HNSCC cells
by targeting the EGFR.
GSPs reduce the level and activity of NF-kB/p65 in
HNSCC cells: NF-kB is an important mediator of cell
invasion
As NF-kB is a down-stream target of EGFR, we assessed
whether GSPs affect the levels and activation of NF-kB in OSC19
cells. OSC19 cells were incubated with various concentrations of
GSPs (10, 20 and 40 mg/mL) for 48 h, and thereafter the cells
were harvested and cytoplasmic and nuclear fractions were
prepared for western blot analysis. As shown in Figure 4A,
western blot analysis of the nuclear fraction revealed that
treatment of cells with GSPs reduced the translocation of NF-
kB/p65 into the nucleus in a concentration-dependent manner.
The results also indicated that treatment with GSPs resulted in
the downregulation of IKKa whereas increases the levels of
IkBa, which leads to the inactivation of NF-kB and its
translocation to the nucleus. The activity of NF-kB/p65 was
significantly reduced in a concentration-dependent manner (30–
75%, P,0.05, P,0.001) after treatment of the cells with GSPs
(Figure 4B). Similar results were observed when the OSC19 cells
were treated with erlotinib under identical experimental
conditions (Figures 4C, 4D). To further assess whether NF-kB
has a role in HNSCC cell invasion, OSC19 cells were treated
with caffeic acid phenethyl ester (0, 5.0 and 10.0 mg/mL), a
potent inhibitor of NF-kB, and cell invasion was determined. As
shown in Figure 4E, treatment of OSC19 cells with caffeic acid
Figure 5. Both GSPs and MEK inhibitor (UO126) inhibit OSC19
cell invasion by reducing activation of ERK1/2. (A) GSPs inhibit
the activation of ERK1/2 in OSC19 cells in a dose-dependent manner.
OSC19 cells were treated with indicated concentrations of GSPs for
48 h, the cells harvested and whole cell lysates subject to western
blotting using antibodies specific for total ERK1/2 and phosphorylated
ERK1/2. (B) Similarly, the treatment of OSC19 cells with UO126, a MEK
inhibitor, (80 mM) for 48 h inhibited the activation of ERK1/2 in cells as
determined by western blot analysis. Representative blots are shown
from three separate experiments. (C) OSC19 cells were treated with
UO126 (80 mM) for 48 h and cell invasion assessed as described in
Figure 1. Crystal violet staining of the membrane indicated that UO126
inhibited the invasive potential of cells as compared to non-UO126-
treated control cells. (D) The data on cell invasion are summarized and
expressed as the mean number of invasive cells6SD/microscopic field,
magnification: 610. Experiments were repeated two times. Significant
difference versus control
*P,0.001.
doi:10.1371/journal.pone.0031093.g005
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(38% and 64%; P,0.05, and P,0.001) compared to non-caffeic
acid phenethyl ester-treated control cells, and these results are
similar to that observed on treatment of the cells with GSPs
(Figure 2A, 2B).
GSPs inhibit the expression of NF-kB-targeted proteins in
OSC19 cells
As the functional activity of NF-kB is mediated through its
targeted proteins, we further determined whether GSPs affect the
levels of NF-kB-responsive proteins associated with cancer cell
invasion, including MMPs, COX-2, iNOS and VEGF, in
HNSCC cells. As shown in Figure 4F, western blot analysis
revealed that treatment of OSC19 cells with GSPs resulted in a
markedly reduced levels of MMP-2, MMP-9, COX-2, iNOS and
VEGF proteins as compared to non-GSPs-treated controls, which
is indicated by the visual intensity of the respective bands.
GSPs as well as MEK inhibitor (UO126) inhibit the
phosphorylation of ERK1/2 in OSC19 cells: UO126
reduces the invasive potential of OSC19 cells
Mitogen-activated protein kinases (MAPKs) are down-stream
targets of EGFR signaling as well as upstream regulators of NF-
kB, and have been implicated in cancer cell metastasis [21].
Therefore, we examined the effect of GSPs on activation of the
extracellular-signal regulated kinase (ERK1/2) in HNSCC cells.
Western blot analysis revealed that treatment of OSC19 cells with
GSPs for 48 h inhibited the phosphorylation of ERK1/2 in a
dose-dependent manner, as shown in Figure 5A. Similarly, the
treatment of cells with UO126 also inhibited the phosphorylation
of ERK1/2 (Figure 5B). We then determined the role of activated
ERK1/2 on OSC19 cell invasion. The cell invasion assay revealed
that treatment of OSC19 cells with UO126 for 48 h significantly
inhibited (68%, P,0.001) the invasiveness of cells (Figure 5C, 5D).
A summary of data obtained from three independent experiments
is shown in Figure 5D.
GSPs promote transition of the mesenchymal state to the
epithelial state in HNSCC cells
Upregulation of EGFR and activation of downstream targets
like ERK1/2 and NF-kB play critical roles in the EMT
[15,16,21], which has been implicated in cancer cell invasion
and metastasis. Therefore, we checked the effect of GSPs on the
EMT in OSC19 cells. For this purpose, OSC19 cells were
incubated with varying concentrations of GSPs and erlotinib
separately for 48 h. Thereafter, cells were harvested and cell
Figure 6. Treatment of OSC19 cells with GSPs or erlotinib results in reversal of epithelial-to-mesenchymal transition. (A) Treatment of
OSC19 cells with GSPs for 48 h enhanced the levels of epithelial biomarkers in the cells as assessed by western blotting, including the levels of E-
cadherin, keratin-8, keratin-18 and desmoglein-2. (B) Simultaneously, the levels of mesenchymal biomarkers in cells, such as, N-cadherin, vimentin,
fibronectin and Slug, were decreased in a dose-dependent manner. (C and D) Under identical conditions, treatment of OSC19 cells with erlotinib also
resulted in reversal of epithelial-to-mesenchymal transition in a dose-dependent manner. Presented blots are representative of three independent
experiments with similar results.
doi:10.1371/journal.pone.0031093.g006
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mesenchymal biomarkers using western blot analysis. Western
blot analyses revealed that GSPs increased the levels of epithelial
biomarkers, such as E-cadherin, keratin 8, keratin 18 and
desmoglein 2 in OSC19 cells in a dose-dependent manner
compared to untreated controls (Figure 6A). In contrast, the
levels of mesenchymal biomarkers, such as N-cadherin, vimen-
tin, fibronectin and Slug, were reduced in OSC19 cells after
treatment with GSPs in a dose-dependent manner (Figure 6B).
Similar to GSPs, the treatment of OSC19 cells with erlotinib
resulted in an increase in the levels of epithelial biomarkers
(Figure 6C) and a decrease in the levels of mesenchymal
biomarkers in OSC19 cells (Figure 6D).
Discussion
The therapeutic potential, including antitumor activity, of GSPs
has been reported in various preclinical models [7–9,22,23];
however, the effect of GSPs on the invasive potential of cancer
cells is less explored. In the current study, we investigated the
potential utility of GSPs in the prevention of invasiveness of
HNSCC cells. HNSCCs can arise from several different sub-sites.
In our preliminary studies, we tested the invasiveness of HNSCC
cell lines generated from the oral cavity, larynx, and pharynx. The
results suggested that, under the experimental conditions used in
these studies, these cell lines exhibited greater invasive potential
than normal bronchial epithelial cells. The invasive potential of
the metastatic OSC19 cell line that originated from the tongue was
greater than the other cell lines (SCC1, SCC5, FaDu).
GSPs were found to inhibit the invasiveness of OSC19 cells in a
dose-dependent manner and this inhibitory effect of GSPs was
associated with the downregulation of EGFR expression in the
OSC19 cells. The OSC19 cells overexpress EGFR and the
inhibition of EGFR by GSPs may contribute to the inhibition of
cell invasion of these cells. This concept is supported by the
evidence that treatment of the OSC19 cells with gefitinib or
erlotinib, small molecule inhibitors of EGFR, resulted in a
reduction in the cell invasion ability. It has been reported that
inhibitors of EGFR can prevent the growth and progression of
HNSCCs; however, their long term use may also induce some
form of toxicity [13]. Notably, significant toxicity has not been
associated with the use of GSPs in animal models [7–9,22].
NF-kB is a downstream target of EGFR, and activation of NF-
kB has been identified as an important regulator of cancer cell
invasion, metastasis and angiogenesis [14,24,25]. Therefore, we
checked the effect of GSPs on the basal levels of NF-kB in OSC19
cells and found that treatment of these cells with GSPs results in
downregulation as well as inactivation of the NF-kB pathway in a
dose-dependent manner. GSPs decrease the levels of IKKa which
is responsible for inactivation of NF-kB. Treatment of cells with
caffeic acid phenethyl ester, an inhibitor of NF-kB, resulted in an
inhibitory effect on the invasion of HNSCC cells. NF-kB-targeted
proteins, such as MMPs, COX-2, iNOS and VEGF, have been
implicated in tumor angiogenesis and tumor cell migration.
Treatment of OSC19 cells with GSPs down-regulates the
expression of these NF-kB-targeted proteins, which supports the
evidence that NF-kB has a role in invasion of HNSCC cells, and
that the inhibitory effect on cell invasion by GSPs is mediated, at
least in part, through the inactivation of NF-kB. It is important to
mention that all these effects of GSPs may not be solely caused by
the inhibition of EGFR; other factors or targets may also play a
role and that need to be identified. Proteins of the MAPK family
are also downstream targets of EGFR and have been shown to
play a crucial role in cancer cell migration/invasion. Activation of
the proteins of MAPK family leads to the activation of NF-kB.
Our results show that inhibition of invasiveness of OSC19 cells by
GSPs is associated with the inhibition of ERK1/2 phosphoryla-
tion. The use of MEK inhibitor (UO126) blocked the cell invasion
capacity of OSC19 cells, and this function of UO126 is similar to
the action of GSPs. These observations suggest a possible
involvement of the ERK1/2-NF-kB pathway in inhibition of the
invasive potential of HNSCC cells by GSPs.
In addition to the role of NF-kB in cancer biology, such as in
tissue invasion, cell migration and metastasis, NF-kB has been
identified as an important regulator of EMT in several cancer cell
types [14,24,25]. EMT plays a major role in invasion and
metastasis of epithelial tumors. EMT can render tumor cells
migratory and invasive through the involvement of all stages,
invasion, intravasation and extravasation [16,26]. During the
EMT stage, cells change from an epithelial to a mesenchymal
phenotype. They lose their characteristic epithelial traits and
instead gain properties of mesenchymal cells. This process is
coordinated primarily by the loss of epithelial biomarkers such as
E-cadherin and certain cytokeratins, concomitant with the
acquisition of mesenchymal markers, such as vimentin, fibronec-
tion, N-cadherin, etc.. In the present study, we found that GSPs
treatment of OSC19 cells resulted in the suppression or loss of
mesenchymal biomarkers while restoring the levels of epithelial
biomarkers, which suggests that GSPs have the ability to reverse
the EMT process in HNSCC cells. This may be one of the possible
Figure 7. Summary of the action of GSPs on the prevention of
HNSCC cell invasion. GSPs inhibit the expression levels of EGFR in
human HNSCC cells, which plays a critical role in inactivation of ERK1/2,
NF-kB and reversal of epithelial-to-mesenchymal transition. Collectively,
these effects lead to GSPs-induced inhibition of cancer cell invasion.
However, all these effects of GSPs may not be solely caused by the
inhibition of EGFR expression; other targets may also play a role and
that need to be further identified.
doi:10.1371/journal.pone.0031093.g007
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HNSCC cells thereby inhibiting their invasion in our in vitro
model.
Biological activity of phytochemicals largely depends on their
bioavailability. The study of bioavailability and metabolism of any
agent or phytochemical is an important part of all investigations.
Some studies have been performed to examine the bioavailability
and metabolism of proanthocyanidins. Studies have shown that
polymeric proanthocyanidins are not absorbed as such in the gut
[27]. The detection of proanthocyanidin dimers B1 and B2 in
human plasma was reported in some studies [28,29]. The
absorption of these dimers was significantly lower than that of
the monomeric flavanols [29]. However, these compounds were
found to protect the intestinal mucosa against oxidative stress or
the actions of carcinogens. Additionally, proanthocyanidins have
been found to be quite stable, and GSPs are stable at least 2 years
if stored in refrigerator at 4uC.
Together, the results from this study have identified for the first
time that bioactive proanthocyanidins from grape seeds inhibit the
invasiveness of human HNSCC cells and that this effect involves:
(i) the inhibitory effect of GSPs on EGFR expression, (ii) the
inhibitory effect of GSPs on the activation of the ERK1/2 proteins
and inactivation of NF-kB, and (iii) reversal of the EMT. These
events and observations are summarized in Figure 7. Further in
vitro and in vivo studies may help to develop GSPs as a
pharmacologically safe bioactive chemotherapeutic or chemopre-
ventive agent when used either alone or in combination with other
anti-metastatic drugs for the treatment of HNSCC in humans.
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